Fundamental Analysis of THIRD HARMONIC BIO INC(NASDAQ:THRD) stock

Fundamental Rating

Taking everything into account, THRD scores 3 out of 10 in our fundamental rating. THRD was compared to 198 industry peers in the Pharmaceuticals industry. THRD has a great financial health rating, but its profitability evaluates not so good. THRD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

THRD had negative earnings in the past year.

THRD had a negative operating cash flow in the past year.

1.2 Ratios

THRD has a better Return On Assets (-11.10%) than 72.82% of its industry peers.

With a decent Return On Equity value of -11.46%, THRD is doing good in the industry, outperforming 78.97% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-11.1%
ROE	-11.46%
ROIC	N/A

ROA(3y)-15.26%

ROA(5y)N/A

ROE(3y)-15.86%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

THRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for THRD has been increased compared to 1 year ago.

THRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

THRD has an Altman-Z score of 33.04. This indicates that THRD is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 33.04, THRD belongs to the best of the industry, outperforming 95.90% of the companies in the same industry.

There is no outstanding debt for THRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	33.04

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

THRD has a Current Ratio of 50.29. This indicates that THRD is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of THRD (50.29) is better than 99.49% of its industry peers.

A Quick Ratio of 50.29 indicates that THRD has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 50.29, THRD belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	50.29
Quick Ratio	50.29

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for THRD have decreased by -5.71% in the last year.

EPS 1Y (TTM)-5.71%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q52.78%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

THRD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.85% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-41.44%

EPS Next 2Y-34.76%

EPS Next 3Y-29.85%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

THRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year THRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as THRD's earnings are expected to decrease with -29.85% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-34.76%

EPS Next 3Y-29.85%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for THRD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THIRD HARMONIC BIO INC

NASDAQ:THRD (4/23/2024, 9:09:56 AM)

11.67

+0.02 (+0.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap475.09M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-11.1%
ROE	-11.46%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	50.29
Quick Ratio	50.29
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-5.71%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-41.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

THIRD HARMONIC BIO INC (THRD)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens